Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Teva Receives European Commission Approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Rabu, 26 November 2025 - 04:34:43 Wib
Globenewswire

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Ahad, 23 November 2025 - 03:32:24 Wib
Globenewswire

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

Rabu, 19 November 2025 - 20:34:20 Wib
Globenewswire

AUSTEDO® (deutetrabenazine) Tablets and AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Selasa, 11 November 2025 - 02:36:18 Wib
Globenewswire

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Kamis, 06 November 2025 - 03:32:51 Wib
Globenewswire

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Senin, 03 November 2025 - 21:44:06 Wib
Globenewswire

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Ahad, 02 November 2025 - 01:12:03 Wib
Globenewswire

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Rabu, 22 Oktober 2025 - 02:44:29 Wib
Globenewswire

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Sabtu, 11 Oktober 2025 - 02:25:54 Wib
Globenewswire

Teva Releases Q3 2025 Aide Memoire

Sabtu, 27 September 2025 - 02:46:01 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sabtu, 27 September 2025 - 02:45:20 Wib
Globenewswire

Patients Taking AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Reported Symptom Improvement and High Satisfaction

Senin, 22 September 2025 - 02:25:11 Wib
Globenewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Senin, 22 September 2025 - 02:24:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual Meeting

Kamis, 18 September 2025 - 02:37:45 Wib
Berita

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Rabu, 10 September 2025 - 04:08:15 Wib
Globenewswire

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Rabu, 03 September 2025 - 23:16:09 Wib
Globenewswire

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Kamis, 28 Agustus 2025 - 22:10:36 Wib
Globenewswire

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Kamis, 07 Agustus 2025 - 00:14:16 Wib
Globenewswire

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Rabu, 30 Juli 2025 - 21:05:04 Wib
Globenewswire

Teva Releases Q2 2025 Aide Memoire

Jumat, 27 Juni 2025 - 03:41:22 Wib
Globenewswire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Jumat, 27 Juni 2025 - 03:23:49 Wib
Globenewswire

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Senin, 16 Juni 2025 - 22:13:00 Wib
Globenewswire

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Rabu, 04 Juni 2025 - 05:00:00 Wib
Globenewswire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Selasa, 03 Juni 2025 - 18:30:00 Wib
Globenewswire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Senin, 02 Juni 2025 - 03:23:09 Wib